Open Access
Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE
Marc Humbert,Richard Beasley,J. Ayres +2 more
- pp 425-434
About:
The article was published on 2017-01-01 and is currently open access. It has received 848 citations till now. The article focuses on the topics: Omalizumab.read more
Citations
More filters
Journal ArticleDOI
Current and future applications of the anti-IgE antibody omalizumab
Cristoforo Incorvaia,Marina Mauro,Gian Galeazzo Riario-Sforza,Franco Frati,Francesco Tarantini,Maurizio Caserini +5 more
TL;DR: There are data indicating the usefulness of omalizumab when used in combination with allergen specific immunotherapy, in terms of reducing the adverse reactions to treatment and increasing the clinical efficacy.
Journal ArticleDOI
Omalizumab in the management of patients with allergic (IgE-mediated) asthma
TL;DR: In clinical trials in adults and adolescents, omalizumab reduced asthma exacerbations, severe asthma exacerbation, inhaled corticosteroid requirements, and emergency visits, as well as significantly improving asthma-related quality of life, morning peak expiratory flow and asthma symptom scores in patients with severe allergic (IgE-mediated) asthma.
Journal ArticleDOI
Cost-effectiveness of omalizumab add-on to standard-of-care therapy in patients with uncontrolled severe allergic asthma in a Brazilian healthcare setting.
TL;DR: Omalizumab as an add-on therapy is more cost-effective than standard-of-care therapy alone for Brazilian patients with uncontrolled severe allergic asthma, based on the World Health Organization’s cost-effectiveness threshold of up to 3-times the gross domestic product.
Journal ArticleDOI
Long-Term Omalizumab Treatment: A Multicenter, Real-Life, 5-Year Trial.
Arzu Yorgancioglu,Ferda Öner Erkekol,Dilşad Mungan,Münevver Erdinç,Bilun Gemicioglu,Zeynep Ferhan Ozseker,Papatya Bayrak Degirmenci,Sibel Atis Nayci,Aykut Cilli,Füsun Erdenen,Cengiz Kirmaz,Dane Ediger,Arzu Didem Yalcin,Suna Büyüköztürk,Sami Öztürk,Mustafa Gulec,Sacide Rana Işık,Ali Fuat Kalyoncu,Ozlem Goksel,Ömür Aydın,Yavuz Havlucu,Idilhan Ar,Ahmet Erdogdu +22 more
TL;DR: Omalizumab had a significant effect on asthma outcomes and this effect was maintained over 5 years and the drug was found to be generally safe and treatment compliance was good.
Journal ArticleDOI
Cost-effectiveness of omalizumab for the treatment of moderate-to-severe uncontrolled allergic asthma in the United States.
Patrick W. Sullivan,Qianyi Li,S Pinar Bilir,Joseph Dang,Abhishek Kavati,Ming Yang,Yamina Rajput +6 more
TL;DR: Using broader evidence on treatment discontinuation, caregiver burden, and oral corticosteroid reduction from real-world studies may better reflect the effects and value of omalizumab for all healthcare stakeholders.
References
More filters
Journal ArticleDOI
Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials.
Elizabeth F. Juniper,Gordon H. Guyatt,Robert S. Epstein,Penelope J. Ferrie,Roman Jaeschke,T K Hiller +5 more
TL;DR: A questionnaire suitable for all adults with asthma and designed to be responsive to within subject change and therefore may be used as a measure of outcome in clinical trials in asthma is developed.
Allergy, rhinitis, other respiratory diseases Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma
William W. Busse,Jonathan Corren,Bobby Q. Lanier,Margaret McAlary,Angel FowlerTaylor,Giovanni Della Cioppa,Niroo Gupta,Fort Worth +7 more
TL;DR: Omalizumab as discussed by the authors is a recombinant humanized anti-IgE mAb, which forms complexes with free IgE, blocking its interaction with mast cells and basophils.
Journal ArticleDOI
Proceedings of the ATS Workshop on Refractory Asthma Current Understanding, Recommendations, and Unanswered Questions
Sally E. Wenzel,John V. Fahy,Charles G. Irvin,Stephen P. Peters,Sheldon L. Spector,Stanley J. Szefler,Thomas B. Casale,Michelle M. Cloutier,Jack A. Elias,Mark C. Liu,Virginia Taggert +10 more
TL;DR: The proceedings of an American Thoracic Society (ATS)-sponsored workshop are hoped to serve as an aid to begin to define, understand, and manage these refractory patients.
Journal ArticleDOI
The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics
Markus Solèr,J. Matz,Robert G. Townley,R. Buhl,J. O'Brien,Howard Fox,J. Thirlwell,N. Gupta,G. Della Cioppa +8 more
TL;DR: Results indicate that omalizumab therapy safely improves asthma control in allergic asthmatics who remain symptomatic despite regular use of inhaled corticosteroids and simultaneous reduction in Corticosteroid requirement.